CFI and age-related macular degeneration: Since these studies were designed to support the development program of GSK933776 in geographic atrophy, we also used the CFI bioactivity assay to assess whether concentrations and, more importantly, CFI bioactivity changes throughout the AMD disease continuum using a cohort of subjects with various stages of AMD.